Downstream Process Optimisation

Downstream Process Optimisation by New Wave Biotech is an AI-powered bioprocess simulation platform designed to help life sciences companies and scientists accelerate their path to commercial viability. By virtually testing thousands of process configurations in-silico, the platform enables organisations to focus their limited experimental capacity on the highest-potential options, reducing the time and cost associated with traditional bioprocess development.

The platform is built for biomanufacturing teams seeking to optimise product recovery and quality, reduce unit costs, and leverage accumulated historical data as a strategic asset for future R&D projects. A published case study with Multus demonstrates an 8X increase in yield and a 55% cost reduction achieved within a single year.

Challenges with Traditional Bioprocess Optimisation

• Bioprocess optimisation involves over one trillion possible parameter combinations per process, making manual exploration impractical.
• The conventional approach relies on slow, iterative cycles of planning, conducting experiments, analysing results, and interpreting controlled tests on a limited number of factors at a time.
• Individual experiments typically cost between $10,000 and $100,000, and scaling from laboratory to market takes between 3 and 10 years.
• Assessing the commercial and sustainability trade-offs of each process option is equally costly — a single Techno Economic Analysis (TEA) report ranges from $20,000 to $40,000 and can take months to complete.

Key Capabilities of the New Wave Biotech Platform

• AI-powered bioprocess simulation: Predicts quantified outputs, costs, and sustainability impact for any given process configuration, enabling teams to foresee the consequences of decisions before committing to physical experiments.
• In-house optimisation engine: Automatically simulates and compares tens of thousands of scenarios, navigating the vast landscape of process possibilities to surface the options with the highest potential.
• Virtual experiment exploration: Allows scientists to explore and compare process scenarios in-silico, dramatically reducing the need for costly physical trials.
• Continuous model improvement: As empirical experimental data is uploaded, it is used to train and refine predictive models, improving accuracy over time.
• Historical data leverage: Accumulated experimental and process data is transformed into a competitive asset that can inform and accelerate every new R&D project across the organisation.

Core Business Benefits

• Cheaper and faster R&D: By directing experiments toward the best-performing processes identified in-silico, organisations reduce wasted spend and accelerate development timelines.
• Boosted production performance: Optimisation targets higher product recovery and improved product quality.
• Reduced unit costs: The platform optimises for end-to-end process economics, lowering the cost of goods across the production lifecycle.
• Reinforced competitive advantage: Historical data is systematically leveraged to drive new R&D initiatives, compounding the value of past work.

New Wave Biotech offers free consultations with its team of experts, allowing prospective users to explore how the platform can be applied to their specific bioprocess challenges. The platform is positioned for companies at any stage of biomanufacturing development seeking to compress timelines and improve the economics of bringing biological products to market.